Abstract: Baseline minority etravirine RAMs (n) were detected in 8/40 VFs (V90I [2], A98G [1], L100I [1], V106I [1], E138G [1] and Y181C [2]) and 5/38 responders (V90I [3], A98G [1], V106I [1] and E138G [1]).
Abstract: The most frequent emerging non-nucleoside reverse transcriptase inhibitor RAMs detected by PS (>=3 VFs; n) were the etravirine RAMs Y181C (8), V90I (3), L100I (3) and E138A (3).
Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.
PMID: 26651266
2016
AIDS research and human retroviruses
Method: Evidence of transmitted HIV-1 drug resistance (TDR) was defined by the presence of at least one surveillance drug resistance mutation (SDRM) from the consensus genotypic definition of Bennett et al., including major RVP-RAMs L100I+K103N, Y181C/I/V, Y188L, and M230L, and minor RPV-RAMs L100I, K103S, V106A, V179F, and G190A/E/S.
Method: In addition, we defined a list of minor RPV-RAMs that have been observed in in vitro or in vivo selection studies and are included in one or more of clinically widely used genotypic resistance interpretation algorithms ANRS (V24), Rega (V9.1.0), and HIVdb (V7.0.1), encompassing
HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naive and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
Discussion: Previously reported NNRTIs mutations for the 2004 to 2005 period in ARV drug-experienced subjects exposed to AZT or d4T + 3TC or ddI + EFV or NFV or IDV reported K103N at a lower frequency (4.9%), together with mutations L100I (1.2%) and Y318F (1.2%).
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
Method: RT-RAMs were identified and analyzed by using the Stanford Drug Resistance Database for V90I, A98G, L100I/V, K101E/P/Q/H/N, K103N/S/T/Q/E/H/R, V106A/M/I, V108I, E138A/K/Q/G/R, V179D/E/T/F/L, Y181C/I/V/S/F/G, M184I, Y188C/H/L/F, G190A/S/E/Q/C/V/T, H221Y,
Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
PMID: 27124362
2016
Journal of acquired immune deficiency syndromes (1999)
Introduction: A partial list of NNRTI resistance mutations include: L100I, K103N, V106A, E138K, Y181C, Y188L, and H221Y; these mutations can occur singly, or in combinations.
Introduction: However, in clinical trials individuals on an ETR containing regimen who experienced virological failure were infected with viruses that had a combination of RT mutations including V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y1
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
PMID: 27645238
2016
Antimicrobial agents and chemotherapy
Method: The nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant viruses encoding RT mutation K103N, Y181C, Y188L, or L100I/Y181C were constructed by site-directed mutagenesis.
Result: Viral breakthrough with these agents contained HIV-RT mutations commonly associated with clinical resistance development (e.g., E138K and M230I for RPV, L100I for EFV, and M184I/V for FTC).
[Molecular epidemiology and transmission of HIV in Tianjin, 2015].
PMID: 27539349
2016
Zhonghua liu xing bing xue za zhi
Abstract: 5.3% of the NNRTI L100I HIV infectors transmitted the drug-resistant-mutation strain.
Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
PMID: 27541578
2016
Journal of medicinal chemistry
Abstract: Compound 27 was the most potent; compared with ETV, its antiviral efficacy was 3-fold greater against WT, 5-7-fold greater against Y181C, Y188L, E138K, and F227L+V106A, and nearly equipotent against L100I and K103N, though somewhat weaker against K103N+Y181C.
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
PMID: 27231280
2016
The Journal of antimicrobial chemotherapy
Abstract: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate RAMs studied were K65R, L100I, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C and M230I/L in the RT.
From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
HIV mutation literature information.
PMID: 
2016
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT